Drug Trial Radar · NCT04665154
A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jun 7, 2019
Primary completion
Aug 3, 2022
Study completion Aug 3, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is conducted to investigate the safety, tolerability and pharmacokinetics of MAS825 in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
MAS825Drug
single dose i.v. and s.c.
PlaceboDrug
single dose i.v. and s.c.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse EventsTime frame: up to day 253
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Tempe, Arizona
Novartis Investigative Site
Overland Park, Kansas
Novartis Investigative Site
Mere Way, Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.